LabGenomics, Major Executives Buy Shares... "Confidence in Undervaluation and Growth"

Genome molecular diagnostics specialist LabGenomics announced on the 27th that key executives purchased approximately 1 billion KRW worth of the company's shares on the open market. This stock purchase demonstrated the company's confidence in growth and commitment to responsible management.

Prior to this stock purchase, the new and existing management teams formed a one-team approach and mutually agreed on a lock-up (stock sale restriction). As a result, the acquired shares cannot be sold for up to four years. They united with the goal of enhancing corporate value and growing into a global genome molecular diagnostics company.

A company representative stated, “We judged that the current stock price does not reflect the fundamentals and growth potential, which led to the open market purchase. We will strive to grow as a leading domestic genome molecular diagnostics specialist and enhance corporate and shareholder value.”

LabGenomics is targeting the global gene analysis market with NGS (Next-Generation Sequencing)-based genetic testing services. Recently, it has been expanding sales channels to Europe and Southeast Asia, accelerating its global market entry by leveraging abundant NGS clinical data and technological capabilities.

A LabGenomics representative emphasized, “We will enter a second growth phase with successful U.S. market entry through the acquisition of CliaLab and business plans and management strategies aligned with the post-COVID era.”

This content was produced with the assistance of AI translation services.